SEC Filing Summary: Bellevue Life Sciences Acquisition Corp. (BLAC)
Business Context and Reporting Period
This Form 8-K, dated November 12, 2024, reports on the Annual Meeting of stockholders held by Bellevue Life Sciences Acquisition Corp. (BLAC), a Special Purpose Acquisition Company (SPAC). The filing details the approval of charter amendments and the election of directors. Note: The input metadata references "OSR Holdings, Inc.," but the filing text explicitly identifies the registrant as Bellevue Life Sciences Acquisition Corp.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels, as this is a current report regarding corporate governance events rather than a periodic financial statement. However, the following capital structure data is provided:
- Shares Outstanding: 4,041,221 shares of common stock as of the October 17, 2024 record date.
- Redemptions: 1,766,469 shares of common stock were tendered for redemption in connection with the approved proposals.
- Warrant Exercise Price: $11.50 per share.
Material Changes and Corporate Actions
Stockholders approved two significant amendments to the Company's Charter:
- Extension of Business Combination Deadline: The date by which the Company must consummate a business combination was extended from November 14, 2024, to February 14, 2025.
- Removal of Net Tangible Asset (NTA) Requirement: The NTA requirement was removed to expand the methods available to the Company to avoid being subject to SEC "penny stock" rules.
Additionally, all five existing directors were re-elected to the Board of Directors.
Voting Results and Management Commentary
Voting Participation: 2,878,990 shares (approximately 71.24% of outstanding shares) were present in person or by proxy, constituting a quorum.
Proposal Results:
- Extension Amendment Proposal: Approved with 2,874,672 votes FOR and 4,318 votes AGAINST.
- NTA Requirement Amendment Proposal: Approved unanimously with 2,878,990 votes FOR and 0 votes AGAINST.
- Director Elections: All five directors received substantial support, with vote counts ranging from 2,874,583 to 2,878,990 FOR.
Redemption Impact: The filing notes that 1,766,469 shares were tendered for redemption. The filing text does not explicitly state the remaining cash balance or the specific impact on the trust account liquidity post-redemption.
Investor Verification Checklist
- Trust Account Balance: Verify the remaining cash in the trust account after the redemption of 1,766,469 shares to assess liquidity for the extended period.
- Extension Fee Obligations: Confirm if any extension fees were paid into the trust or if additional capital contributions are required to maintain the trust value.
- Target Identification: Review subsequent filings to determine if a specific business combination target has been identified for the new February 14, 2025 deadline.
- Share Count Update: Confirm the updated number of outstanding shares following the redemption process.